Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TLR2 | O60603 | 1/20 | 0.30 |
| ▸ | ERN1 | O75460 | 1/20 | 0.30 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.30 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1397209 | 0.88 | MEN1 (0.31) | MEN1ALDH1A1CYP3A4KMT2A | |
| SCHEMBL1702608 | 0.87 | KMT2A (0.36) | MEN1ALDH1A1CYP3A4KMT2ANFE2L2 | |
| SCHEMBL3367704 | 0.86 | ALDH1A1 (0.36) | MEN1ALDH1A1CYP3A4KMT2ANFE2L2 | |
| SCHEMBL16959513 | 0.86 | MCHR1 (0.37) | MEN1ALDH1A1CYP3A4KMT2ANFE2L2 | |
| SCHEMBL1358939 | 0.82 | HTR6 (0.31) | — | |
| SCHEMBL1702831 | 0.81 | MEN1 (0.33) | MEN1ALDH1A1CYP3A4KMT2AKDM4E | |
| SCHEMBL1397138 | 0.80 | MEN1 (0.30) | MEN1ALDH1A1CYP3A4KMT2A | |
| SCHEMBL16954898 | 0.78 | L3MBTL1 (0.38) | MEN1ALDH1A1CYP3A4KMT2ANFE2L2 | |
| SCHEMBL27602429 | 0.77 | NR2E1 (0.37) | MEN1ALDH1A1CYP3A4KMT2A | |
| SCHEMBL7990624 | 0.75 | TLR2 (0.46) | MEN1ALDH1A1CYP3A4KMT2ANFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107229185-B | Energy-sensitive composition, cured product, and method for producing cured product | 东京应化工业株式会社 | 2022-04-15 | — | — | CN | disclosed |
| CN-107207456-B | Latent acids and their use | 巴斯夫欧洲公司 | 2021-05-04 | — | — | CN | disclosed |
| EP-3253735-B1 | LATENT ACIDS AND THEIR USE | BASF SE (DE) | 2021-03-31 | — | — | EP | disclosed |
| EP-2539316-B1 | LATENT ACIDS AND THEIR USE | BASF SE (DE) | 2019-10-23 | — | — | EP | disclosed |
| US-9994538-B2 | Latent acids and their use | BASF SE (DE) | 2018-06-12 | — | — | US | disclosed |
| US-20180009775-A1 | LATENT ACIDS AND THEIR USE | BASF SE (DE) | 2018-01-11 | — | — | US | disclosed |
| WO-2016124493-A1 | LATENT ACIDS AND THEIR USE | BASF SE (DE) | 2016-08-11 | — | — | WO | disclosed |
| EP-1769286-B1 | OXIME DERIVATIVES AND THE USE THEROF AS LATENT ACIDS | BASF SE (DE) | 2015-09-09 | — | — | EP | disclosed |
| US-9005871-B2 | Sulfonium derivatives and the use therof as latent acids | BASF SE (DE) | 2015-04-14 | — | — | US | disclosed |
| US-8652752-B2 | Sulphonium salt initiators | BASF SE (DE) | 2014-02-18 | — | — | US | disclosed |
| EP-1392675-A1 | SUBSTITUTED OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS | Ciba SC Holding AG (CH) | 2004-03-03 | — | — | EP | disclosed |
| US-20040002007-A1 | Oxime derivatives and the use thereof as latent acids | CIBA SPECIALTY CHEMICALS CORP. | 2004-01-01 | — | — | US | disclosed |
| EP-1344109-A2 | ONIUM SALTS AND THE USE THEROF AS LATENT ACIDS | Ciba SC Holding AG (CH) | 2003-09-17 | — | — | EP | disclosed |
| WO-2003067332-A2 | SULFONATE DERIVATIVES AND THE USE THEROF AS LATENT ACIDS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2003-08-14 | — | — | WO | disclosed |
| EP-1320785-A2 | OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS | Ciba SC Holding AG (CH) | 2003-06-25 | — | — | EP | disclosed |
| US-6512020-B1 | Photosensitive acid-donors in chemically amplified resist formulations. activated by irradiation with actinic electromagnetic radiation and electron beams. | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-01-28 | — | — | US | disclosed |
| WO-2002098870-A1 | SUBSTITUTED OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2002-12-12 | — | — | WO | disclosed |
| WO-2002046507-A2 | ONIUM SALTS AND THE USE THEROF AS LATENT ACIDS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2002-06-13 | — | — | WO | disclosed |
| WO-2002025376-A2 | OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2002-03-28 | — | — | WO | disclosed |
| US-6261738-B1 | LATENT CURING CATALYSTS FOR PHOTORESISTS SUCH AS 2,2,2-TRIFLUORO-1-PHENYL-ETHANONE OXIME-O-METHYL SULFONATE | CIBA SPECIALTY CHEMICALS CORPORATION | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180009775-A1 | LATENT ACIDS AND THEIR USE | LTA, C1S, C9 | MEN1 4625/4885ALDH1A1 217/4885CYP3A4 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.